BioCentury
ARTICLE | Clinical News

ALX-0681: Phase I data

August 24, 2009 7:00 AM UTC

Data from 36 healthy volunteers in a double-blind, placebo-controlled, single and multiple dose Phase I trial showed that daily injections of 10 mg ALX-0681 achieved complete inhibition of ristocetin...